A Medical Clinical Affairs White Paper | December 2020
Authors: Gopa B. Green MD, Graham Abra MD, and Brigitte Schiller MD FACP FASN
Recombinant human erythropoietin revolutionized the treatment of nephrogenic anemia, eliminating the use of androgens and reducing transfusion needs and complications associated with transfusions dramatically since its introduction thirty years ago. Quality of life in patients who were previously transfusion-dependent improved markedly with erythrocyte stimulating agents (ESAs) and their use became progressively more extensive in both end-stage kidney disease (ESKD) patients on dialysis and in patients with chronic kidney disease (CKD) not on dialysis.